Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · July 02, 2022

Cost of Ranibizumab PDS vs Intravitreal Injections for Patients With Neovascular AMD

JAMA Ophthalmology


Additional Info

JAMA Ophthalmology
Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration
JAMA Ophthalmol 2022 Jun 16;[EPub Ahead of Print], S Sood, J Mandell, A Watane, S Friedman, R Parikh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading